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Abstract
Background: Although, chronic hepatitis B (HBV) is considered to be of significant public health importance in
Ghana, not many reviews detailing the burden (prevalence) of the disease have been conducted. This study was
aimed at summarizing the available information and to make an accurate estimate of HBV infection prevalence in
Ghana over the last two decades (1995–2015).
Methods: A systematic search was conducted in PubMed, ScienceDirect, Google Scholar and Africa Journals Online
(AJOL) databases to retrieve primary studies published between 1st January 1995 and 4th October 2015, assessing
the prevalence of HBV among populations in Ghana. This was supplemented by a manual search of retrieved
references.
Results: Thirty (30) studies across all the ten (10) regions of Ghana and involving an overall population size of
105,435 were analyzed. The national prevalence of HBV as determined by HBsAg seropositivity was 12.3 %. HBV
prevalence among voluntary blood donors (VBDs), replacement blood donors (RBDs) and pregnant women were
10.8, 12.7 and 13.1 % respectively. HBV infection prevalence was highest among studies published within the period
1995–2002 (17.3 %), followed by those published within 2003–2009 (14.7 %) and the lowest prevalence rate being
recorded across studies published in the period 2010–2015 (10.2 %). Regional prevalence were determined for
Ashanti, Greater Accra, Eastern, Northern, central and Brong-Ahafo regions as 13.1, 10.6, 13.6, 13.1, 11.5 and 13.7 %
respectively. No aggregate data were derived for Volta, Western, Upper East and Upper West regions. Higher
prevalence of HBV infection was attained for rural (13.3 %) compared to urban settings (12.2 %). Across the country,
highest HBV infection prevalence rates were recorded in persons within the age group 16–39 years.
Conclusion: Hepatitis B infection is clearly an important public health problem in Ghana. The burden of the disease
as dictated by a high prevalence rate calls for urgent public health interventions and strategic policy directions to
controlling the disease to avert any potential future explosion.
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Background
Viral Hepatitis A, B, C, D and E cause significant mor-
bidity and mortality affecting more people worldwide
than even HIV [1]. Nearly 2 billion people across the
world are estimated to be infected with Hepatitis B Virus
(HBV) with nearly a quarter of this having chronic infec-
tion [2, 3]. Each year, over half a million HBV-related
deaths are recorded across the globe [4].
Epidemiological studies have often demonstrated vary-
ing levels of endemicity of HBV worldwide, with highly
endemic areas present in Sub-Saharan Africa (SSA) and
East Asia, where between 5 and 10 % of the adult popu-
lation are deemed to be chronically infected [5]. In
Western Europe and North America, Less than 1 % of
the population is chronically infected. The lifetime risk
of infection from HBV in many African and Asian coun-
tries, the Amazon Basin and parts of the Middle East is
estimated to be more than 60 % [6]. Accurate determin-
ation of the burden of HBV in Africa is difficult owing* Correspondence: asensox215@gmail.com
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to poor record keeping and under-reporting, but esti-
mates put that about 70–95 % of the adult population
show evidence of past exposure to HBV infection and
the HBsAg seroprevalence rate has been put around
6–20 % [6, 7].
Chronic HBV increases individuals’ risk of progressive
liver disease and hepatocellular carcinoma (HCC). In the
natural history of HBV infection, it is estimated that 10
to 33 % of those who develop persistent infection would
end up with chronic hepatitis of which 20 to 50 % may
develop liver cirrhosis [8]. HCC is a highly aggressive
cancer with limited treatment options, often lacking in
many resource-poor settings such as Africa [9]. SSA has
one of the highest HBV-related liver cancer rates in the
world [10]. HBV-related liver cancer also remains the
most common cancer among males and the third most
common cancer among females in the African region
[11, 12]. Of significant importance is that, the average
age of HCC development in Africa is considerably youn-
ger than in other more advanced regions (mean age
33 years compared to 60 years in Western Europe)
meaning HBV-related HCC affects patients in their most
productive and reproductive years [9]. HBV therefore
represents a critical threat to health as well as other de-
velopmental and economic parameters on the African
continent.
In Ghana, HBV is considered to be of significant pub-
lic health importance and a disease that requires greater
attention [13, 14]. Ghana has been grouped as part of
the areas of the world where the prevalence of chronic
HBV infection is high (≥8 %) [9, 15]. Sweitzer et al. for
instance in estimating the global burden of hepatitis B in
2013, put the prevalence of chronic hepatitis B virus in-
fection in Ghana at 12.92 % [3]. However, this was de-
rived from an analysis of only 12 studies. Some experts
have also put the prevalence rate of HBV in Ghana to be
around 10–15 % [16, 17]. A scoping of the literature
identified no other thoroughly conducted reviews specif-
ically summarizing data on prevalence of HBV in Ghana.
This observation points out that although there may
have been significant research into understanding the
burden of HBV in Ghana, the evidence available remains
fragmented. To overcome this perceived gap in evi-
dence compilation, we conducted a systematic review
to thoroughly summarize the available information to-
wards answering the key question; what has been the




Ghana is located along the Gulf of Guinea and Atlantic
Ocean, in the sub region of West Africa 4° north of the
Equator. It has a land mass of 238,537 km2 and a
population of approximately 27million of which 59 % is
rural. Life expectancy at birth in 2013 was 62 years for
males and 64 years for females [18]. The country is di-
vided into ten administrative regions and 216 districts.
Fifty-nine per cent of the Ghanaian workforce is in agri-
culture and almost everyone living in rural areas is in-
volved in farming. Per capita total health expenditure as
a percentage of GDP was 5.4 % in 2013 [18]. About
24.2 % of Ghanaians lived below the poverty line in 2013
[19]. In 2014, Ghana ranked 138 out of 187 countries
and territories, with a Human Development Index value
of 0.573 [20]. Fifty eight percent Ghanaians live less than
30 min of a public or private health facility, with better
geographical within urban centres than rural settings
[21]. The doctor-patient ratio in Ghana in 2011 was
1:10,034 [22] and almost 80 % of Pharmacists are based
in the two largest cities Accra and Kumasi [23]. About
60 % of Ghanaians who report ill or injured consult a
health practitioner while about one-third purchase medi-
cines directly from retail drug outlets [21].
Search strategy
To identify relevant studies, we conducted a structured
review of the literature followed by an analysis of the re-
ported prevalence rates. The review was conducted in
accordance with the PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) Statement
[24]. A comprehensive search was conducted in
PubMed, Science Direct, Google scholar, and Africa
Journals Online (AJOL) databases. The key words used
were Hepatitis B, Hepatitis B surface antigen, prevalence,
Ghana, and similar terms such as HBV, HBsAg, were
crossed. The main limits used were ‘Humans’ and
‘English’.
Inclusion and exclusion of studies
We included only primary studies published in peer-
reviewed Journals between 1st January 1995 and 4th
October 2015, which reported prevalence of HBV in a
sample population in Ghana. Study quality was assessed
using a 12-point scoring system based on the Downs
and Black checklist as adopted in similar reviews
[25, 26]. These were: (objective of the study clearly
described, study design clearly stated, participants
representative of the population from which they
were recruited, participants accrued during the same
time period, modest sample size, management of
missing data, age, gender and other characteristics
explored/reported, e.g. were confounders reported,
was detection method of HBV reported, were poten-
tial biases reported, was outcome clearly described?),
the assessment also included other items known to
be associated with study quality [26]. Studies were
graded as high, medium or low based on quality
Ofori-Asenso and Agyeman BMC Infectious Diseases  (2016) 16:130 Page 2 of 15
scores. As globally agreed, laboratory diagnosis of
hepatitis B infection focuses on the detection of the
hepatitis B surface antigen HBsAg [5, 27]. Studies
were included only if they presented HBV prevalence
based on HBsAg seropositivity. Each study was is-
sued with a unique number for identification pur-
poses and the following descriptive information
collected; author details, year of publication, region
of Ghana, type of study population, mean age of
subjects, number of subjects involved (sample size),
setting (rural or urban) and the HBV prevalence (as
defined by HBsAg seropositivity). Study data were
extracted by RO and Cross checked by AA. Where
there were disagreements, these were resolved by
consensus-based discussions.
Data analysis
The studies’ results were analyzed by meta-analysis pro-
portions which was performed with StatsDirect statis-
tical software version (Version 3.0.0, StatsDirect Ltd,
Cheshire UK) [28]. Individual study proportions were
assessed at 95 % confidence interval (CI) as well as the
pooled effect. Test for heterogeneity was performed for
all the proportions based on Cohran’s Q and degree of
inconsistency (I2) [29]. In all the summary or pooled
analysis, random effect model was adopted over fixed ef-
fect model due to the presence of heterogeneity resulting
from variations of effects from individual studies con-
firmed by I2 > 0 %. For all computations, statistical
significance was set at p < 0.05. We conducted sub-
analyses for the periods within which studies were pub-
lished (1995–2002, 2003–2009 and 2010–2015), among
diverse population sub-groups (e.g. voluntary blood do-
nors, family replacement donors and pregnant women &
parturients) and across the various regions of Ghana.
Ethical approval
This study did not require an ethical approval as it was
based on information/data retrieved from published
studies already available in the public domain.
Results
Studies identification and retrieval
Figure 1 outlines the schematic flow of the studies iden-
tification and inclusion processes. A total of 1,059 arti-
cles were identified by literature search. After the
exclusion of duplicates and irrelevant studies based on
titles and abstracts, 31 articles were retrieved for detailed
full-text analysis. Out of the 30 studies, 28 met the in-
clusion criteria for addition to the review. Two (2) add-
itional studies were retrieved from the reference
screening bringing the total number of studies included
in the review to 30 [8, 30–58]. The 30 studies (Table 1)
included in the review reported prevalence based on an
overall population sample size of 105,435 across all the
ten (10) regions of Ghana. The regional distribution of
studies were, Ashanti (15), Greater Accra (5), Northern
(2), Brong-Ahafo (2), Central (1), Eastern (1), Upper East
Fig. 1 Schematic flow diagram of studies’ retrieval process
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Table 1 A summary of the descriptive characteristics of included studies
Study No Author Details Year of
Publication
Design Region of study Study population Age group Setting Sample
size(n)
Method HBsAg + (%) Quality
Grade
1 Addai-Mensah et al. [30] 2015 Cross-sectional Ashanti Blood donorsb 17–60 Urban 400 Rapid test 6.75 % Medium
2 Adjei et al. [31] 2006 Cross-sectional Eastern & Greater Accra Prison inmates & Officers 17–84 Urban 363 ELISA 14.3 % High
3 Adjei et al. [32] 2008 Cross-sectional National (Excludes Upper
East & West)
Prison inmates & Officers 16–84 Urban 1811 ELISA 22.1 % High
4 Allain et al. [33] 2003 Cross-sectional Ashanti Blood donors & Patients 16–59 Urban 383 Mixed methods 13.85 % High
5 Allain et al. [34] 2009 Cross-Sectional Ashanti Blood donors >16 years Urban 51100 Rapid test 11.3 % High
6 Allain et al. [35] 2010 Cross-sectional Ashanti Blood donors 31.0a Urban 11000 Rapid test 14.2 % High
7 Amidu et al. [36] 2010 Cross-sectional Upper East Blood donors 17–58 Urban 4146 Rapid test 12.64 % Medium
8 Amidu et a.l [37] 2012 Cross sectional Ashanti Community screenees 15–38 Urban 783 Rapid test 8.68 % High
9 Antwi-Baffour et al. [38] 2014 Cross sectional Greater Accra Sickle cell patients n.s Urban 202 Rapid test 3.50 % Low
10 Apea-Kubi et al. [39] 2006 Cross-sectional Greater Accra Pregnant & non-pregnant
women
29.6a Urban 517 Rapid test 16.8 % High
11 Blankson et al. [8] 2005 Case-control Greater Accra Cirrhotic & non-cirrhotic
patients
15–90 Urban 350 ELISA 14.6 % High
12 Candotti et al. [40] 2007 Cross-sectional Ashanti Pregnant women n.s Urban 1368 Rapid test 16.0 % High
13 Cho et al. [41] 2012 Cross-sectional Eastern Pregnant Women n.s Urban 1500 Rapid test 10.6 % High
14 Damale et al. [42] 2005 Cross-sectional Greater Accra Parturients (pregnant
women)
27.0a Urban 638 n.s 10.5 % Medium
15 Dongdem et al. [43] 2012 Cross-sectional Northern Blood donors 20–29 years Urban 6321 Rapid test 11.5 % High
16 Ephraim et al. [44] 2014 Cross-sectional Central Type 2 Diabetics n.s Urban 110 Rapid test 5.50 % Medium
17 Ephraim et al. [45] 2015 Cross-sectional Ashanti Pregnant women 10–40 year Urban 168 Rapid test 16.0 % Medium
18 Geretti et al. [46] 2010 Cross sectional Ashanti HIV patients n.s Urban 838 Mixed methods 16.7 % High
19 Kubio et al. [47] 2012 Report review Northern Blood donors n.s Rural 853 n.s 7.50 % Low
20 Matinson et al. [48] 1996 Cross-sectional Ashanti Children 6–18 Rural 803 immunoassay 15.8 % Medium
21 Matinson et al. [49] 1998 Cross-sectional Ashanti Community screenees . > 1 Rural 1385 immunoassay 20.9 % Medium
22 Mutocheluh et al. [50] 2014 Cross-sectional Brong-Ahafo Blood donors 17–57 Urban 164 ELISA 14.6 % High
23 Nkrumah et al. [51] 2011 Cross-sectional Ashanti Blood donors 26–35 years Rural 2773 Rapid test 10.53 % Medium
24 Nsiah et al. [52] 2012 Cross-Sectional Ashanti Sickle cell patients 10–18 Urban 330 Immunoassay 3.60 % Low
25 Owiredu et al. [53] 2012 Cross-sectional National (all regions) Blood donors n.s Urban 480 Mixed methods 8.13 % High


















Table 1 A summary of the descriptive characteristics of included studies (Continued)
27 Rufai et al. [55] 2014 Cross-sectional Ashanti Blood donors 16–59 Urban 150 Immunoassay 13.3 % Medium
28 Sagoe et al. [56] 2012 Cross-sectional Greater Accra HIV patients ≥18 years Urban 138 ELISA 13.0 % High
29 Sarkodie et al. [57] 2001 Cross-sectional Ashanti Blood donors 16–52 Urban 3587 Mixed methods 15.3 % High
30 Walana et al. [58] 2014 Cross-sectional Brong-Ahafo Blood donors 20–49 years Urban 3402 ICT 9.60 % Medium
a average, HBsAg Hepatitis B surface antigen, n.s not specified, VBD Voluntary blood donor, ELISA Enzyme-Linked Immunosorbent assay, ICT immunochromatography, bBlood donors is used to represent either voluntary


















(1), two (2) inter-regional studies as well as one (1) na-
tional study involving all 10 regions. About 77 % (23/30)
of the studies were published in the years 2006–2015
compared to 23 % (7/30) for the period 1995–2005. A
significant proportion of the studies (87 %, 26/30) were
conducted in urban settings. Also, about 60 % (18/30) of
the studies were published within the last 5 years (2010–
2015) of the review period. Across studies, the sample
sizes ranged from 110 to 51,100. About 47 % (14/30) of
the studies were conducted in blood donors (voluntary
and replacement family members). Only 20 % (6/30) of
studies were conducted exclusively in disease-specific
patient groups (type-2 diabetes, HIV, Sickle cell anemia
and cirrhosis). The overall quality grading identified 57,
33 and 10 % of studies to be of high, moderate and low
quality respectively.
Overall national prevalence
Of the 30 studies, the reported prevalence rates ranged
from 3.5 to 22.1 % (Table 1). In 83 % (25/30) of studies,
the reported prevalence rates exceeded 8 %; the level used
to define the endemicity level of an area as high. In 20 %
(6/30) of studies, the reported prevalence was at least
twice the 8 %. The pooled prevalence rate (Fig. 2) nation-
ally across the 30 studies was 12.3 % (95 % CI 11.3 to 13.4;
P < 0.0001). The result of heterogeneity was also 94.6 %
(95 % CI 93.6 to 95.4 %) for the degree of inconsistency.
There was no evidence of publication bias with
Egger’s test having a P = 0.5273, whereas Begg’s test
had a P = 00.8045. This was depicted graphically by a
funnel plot which showed a near symmetrical display
of prevalence reported by various studies (Fig. 3).
Blood donors
Fourteen studies comprising a total population sample
size of 93,990 presented HBV prevalence among
blood donors (Voluntary and replacement blood do-
nors). The HBV prevalence rate among these blood
donors (BDs) as presented by these studies was within
the range 6.75–15.3 %. For the 14 studies, 86 % (12/14) re-
ported prevalence rates above 8 %, the level used to define
the endemicity level in an area as high [7]. The pooled
prevalence rate (Fig. 4) across the 14 studies was 11.6 %
(95 % CI 10.6 to 12.6; P < 0.0001). The result of heterogen-
eity was also 93.2 % (95 % CI 90.8–94.8 %) for the degree
of inconsistency. Of the 14 studies on blood donors, 7
Fig. 2 Forest plot of HBV infection prevalence rates in Ghana for studies published from 1995 to 2015
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studies provided individual prevalence on voluntary blood
donors (VBDs) and replacement donors (RBDs) based on
a total sample size of 80,709 (VBDs = 44,213, RBDs =
36,496). Among these studies, the pooled HBV preva-
lence among VBDs was 10.8 % (95 % 8.6 to 13.2;
P < 0.0001) whereas among RBDs the prevalence rate
was 12.7 % (95 % 11.1 to 14.4; P < 0.0001). The
difference (1.90 %; 95 % CI = 1. 5 to 2.4 %) in HBV
prevalence rate between the two donor types was sta-
tistically significant (P < 0.0001).
Pregnant women & parturients
A total of 5 studies presented HBV prevalence rates
among pregnant women and parturients. The combined
Fig. 3 Bias Assessment plot of studies reporting HBV prevalence in Ghana from 1995 to 2015
Fig. 4 Forest plot of HBV infection prevalence rates among blood donors (VBDs & RBDs) in Ghana
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sample size across these studies was 3,968. The HBV
prevalence rate in this group ranged from 10.5–16.0 %.
The pooled prevalence rate (Fig. 5) across the 5 studies
was 13.1 % (95 % CI = 10.4 to 16.0 %; P < 0.0001). The
result of heterogeneity was also 82.9 % (95 % CI = 51.2
to 90.9 %) for the degree of inconsistency. The difference
in prevalence rate (1.5 %) between the pregnant & par-
turient women population and the general population
was not statistically significant (P = 0.1324).
Prevalence related to socio-demographic characteristics
Across studies included in the review, there was re-
markable diversity in participants’ age groups, al-
though, majority of the studies were conducted in
adult populations (>16 years). The most prevalent age
groups were not specified in 15 studies [31, 34, 40,
44–47, 50–54, 56, 57]. One study reported the highest
prevalence of HBV infection in participants aged over
40 [33], while 9 studies reported in those aged 16–39
years. In 3 studies, the most prevalent HBV partici-
pants were aged ≥20 years [49, 55. 58]. In one (1)
study the most prevalent HBV participant population
was <16 years [49] where as in two (2) studies no ob-
servable difference was observed among different age
groups [41, 48]. The gender of the participants was
not specified in 5 studies [46, 47, 52–54]. Five studies
restricted to females [39–42, 45] and no study re-
stricted to males only. Two studies [48, 51] docu-
mented no difference among male and female
participants. Five (5) studies reported higher HBV
prevalence among male participants in comparison
with females [30, 36, 37, 49, 58] while opposite re-
sults were reported in two studies [32, 38]. One na-
tional study reported higher infection rate in females
than males [32]. Two studies reported higher preva-
lence in married participants than unmarried persons
[42, 50] whereas one study reported opposite results
[32]. Two studies documented history of previous
blood donation and one indicated higher infection in
persons with previous history of blood donation [32]
while the other study demonstrated no difference with
blood donation non-recipients [50]. One study re-
ported higher prevalence in homosexuals compared to
heterosexuals [32].
Prevalence comparison in rural and urban settings
Four (4) studies were conducted within rural settings.
These studies presented HBV based on a combined sam-
ple size of 5,814. The pooled prevalence rate (Fig. 6)
across the studies conducted in rural settings was 13.3 %
(95 % CI 8.2 to 19.4; P < 0.0001). The result of hetero-
geneity was also 97.3 % (95 % CI = 95.9 to 98.1 %).
Twenty-six (26) studies were conducted within urban
settings. These studies presented HBV based on a com-
bined sample size of 99,621. The pooled prevalence rate
(Fig. 7) across the studies conducted in urban settings
was 12.2 % (95 % CI = 11.1 to 13.3; P < 0.0001). The re-
sult of heterogeneity was also 94.1 % (95 % CI = 92.8 to
95.0 %). The difference (1.1 %; 95 % CI = 0.21 to 2.02 %)
in HBV prevalence rates across studies conducted in
urban setting and those in rural settings was statistically
significant (P = 0.0129).
Fig. 5 Forest plot of HBV infection prevalence rates among pregnant women and parturients in Ghana
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HBV prevalence by region
Eight (8) studies presented HBV prevalence rates for the
Greater Accra region, the second most populous region
in Ghana. Among these studies, the HBV prevalence
rates ranged from 0 to 16.8 %. The studies presented
HBV prevalence based on a total population of 2,416.
The pooled prevalence rate across the eight (8) studies
was 10.6 % (95 % CI = 7.3 to 14.3 %; P < 0.0001). The re-
sult of heterogeneity was also 86.5 % for the degree of
inconsistency. Five (5) studies presented HBV prevalence
rates for the Brong-Ahafo region. Among these studies,
the HBV prevalence rates ranged from 6.0 to 24.5 %.
The studies presented HBV prevalence based on a
total population of 3,828. The pooled prevalence rate
across the 4 studies was 13.7 % (95 % CI = 7.1 to
22.1 %; P < 0.0001). The result of heterogeneity was
also 91.92 % for the degree of inconsistency. Four (4)
studies presented HBV prevalence rates for the East-
ern region. Among these studies, the HBV prevalence
rates ranged from 10 to 20 %. The studies presented
HBV prevalence based on a total population of 1,766.
The pooled prevalence rate across the 4 studies was
13.6 % (95 % CI = 9.3 to 18.5 %; P < 0.0001). The re-
sult of heterogeneity was also 64.3 % for the degree
of inconsistency. Three (3) Studies presented HBV
prevalence rates for the central region, with prevalence
rates ranging from 5.5 to 22.8 % based on a sample size of
796. The pooled prevalence rate across the 3 studies was
11.5 % (95 % CI = 3.9 to 22.5 %; P < 0.0001). The result of
heterogeneity was also 93.28 % for the degree of in-
consistency. Prevalence data for the Northern region,
the largest region in Ghana was retrieved from four
(4) studies. Among these studies, the HBV prevalence
rates ranged from 7.5 to 24.7 %. The studies pre-
sented HBV prevalence based on a total population
of 7,488. The pooled prevalence rate across the 4
studies was 13.1 % (95 % CI = 8.6 % to 19.8; P < 0.0001).
The result of heterogeneity was also 93.93 % for the
degree of inconsistency. For Ashanti region, the most
populous region in Ghana, prevalence data were re-
trieved from seventeen (17) studies comprising a
combined sample size of 84,694. The HBV prevalence
rate for this region ranged from 3.6 to 20.9 %. The
pooled prevalence rate across the 17 studies was
13.1 % (95 % CI 11.7 to 14.5; P < 0.0001). The result
of heterogeneity was also 94.9 % for the degree of in-
consistency. For the Volta, Upper East, Upper West
and Western regions, it was not possible to generate
aggregate data for the Volta, Upper east, upper west
and western regions (Fig. 8).
Prevalence by studies’ publication period
Studies’ publication periods were grouped into 1995–
2002, 2003–2009 and 2010–2015. Three (3), Nine (9)
and eighteen (18) studies were published within these
periods respectively. Among the studies published in the
period 1995–2002, the HBV prevalence ranged from
15.3 to 20.9 % based on a combined sample size of
5,775. The pooled prevalence rate across the studies
published within the period 1995–2002 was 17.3 %
(95 % CI 13.8 to 21.0; P < 0.0001). The result of hetero-
geneity was also 90.83 %. The nine (9) studies published
Fig. 6 Forest plot of HBV prevalence rates for studies conducted in rural settings in Ghana
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within the period 2003–2009 also presented HBV preva-
lence data based on a combined population size of
65,902. The HBV prevalence rates for studies published
within this period ranged from 10.5 to 22.1 %. The
pooled prevalence rate across the studies published
within the period 2003–2009 was 14.7 % (95 % CI 12.5
to 17.0; P < 0.0001). The result of heterogeneity was also
96.19 %. For the 18 studies published within the last
5 years (2010–2015) preceding the conduct of this re-
view, the HBV prevalence ranged from 3.6 to 16.8 %
based on a combined sample size of 33,758. The pooled
prevalence rate (Fig. 6) across the studies published
within the period 2010–2015 was 10.2 % (95 % CI 8.9 to
11.6; P < 0.0001). The result of heterogeneity was also
91.78 %. Hence, the ascending order of prevalence ac-
cording to studies’ publication period was 2010–2015 <
2003–2009 < 1995–2002 (Fig. 9).
Discussion
Hepatitis B virus (HBV) infection is a major problem
of public health in the world particularly in develop-
ing countries. Our review identified the prevalence of
HBV in Ghana as detected by HBsAg seropositivity to
be high at 12.3 %. Our result is comparable to the
prevalence rate reported by Sweitzer et al‘s. review [3]
albeit larger number of studies involved in our study.
The results achieved is also in alignment with the
categorization of Ghana as a high HBV endemic
country (prevalence ≥8 %) [8, 15]. The prevalence rate
achieved significantly exceeds the reported global
prevalence rate of 3.61 % as well as the rate of 8 ·
83 % for the WHO Africa region [3]. In countries like
the US, HBV prevalence rate has been estimated to
be around <0.27 % [59]. In Iran and Kosovo current
estimates put HBV prevalence at 2.14 and 4.2 %
Fig. 7 Forest plot of HBV prevalence rates for studies conducted in urban settings in Ghana
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respectively [60, 61]. Such comparative information
further highlight the enormity of the HBV burden in
Ghana.
Our study also raises serious concerns regarding the
safety of blood supply in Ghana as nearly 1 in 9 blood
donors may be infected with HBV with even higher pro-
portions in replacement blood donors. Ghana has a na-
tional blood policy which requires the screening of all
donated blood for HIV 1 and 2, HBV, Hepatitis C and
Syphilis [62]. Our findings however highlight the need
Fig. 8 Map of HBV prevalence across different regions in Ghana
Fig. 9 A graph of HBV infection prevalence in Ghana according to studies’ publication periods
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for stricter adherence to such policies as the risk of
receiving contaminated blood, which in this is HBV re-
mains high. Additionally, HBV infection among preg-
nant women also remains high (≈1 in 8) and which
justifies the establishment of a national HBV screening
program for all pregnant women in antenatal clinics
throughout Ghana. Additionally, a national policy to
vaccinate all pregnant women who test negative for
HBV should be adopted so as to reduce the risk of
mother to child transmission within the population [45].
A number of factors may account for the observed
high HBV prevalence in Ghana. This includes lack of
adequate information and understanding among
Ghanaians of the transmission dynamics of the virus.
For instance, in an assessment of 200 barbershops
within the Kumasi metropolis, only 7 % knew the
route of transmission of HBV [63]. Akumiah and Sarfo
further point out that, the barber community in
Ghana paid more attention to the decoration (e.g.,
availability of television, air conditioning, sound sys-
tem etc.) other than the risk factors associated with
their profession in the transmission of diseases such as
HBV [64]. Although, the 3 main transmission routes
of HBV in Ghana are transfusion of infected blood,
unprotected sex and mother to child transmission,
and most Ghanaians with chronic hepatitis B were in-
fected at birth or in childhood, HBV has often been
framed as a sexually transmitted infection in many
communities and even among health workers [13].
Stigmatization arising from such misconceptions has
many times prevented patients from finding their way
to proper care and subsequently reducing their infect-
ivity rates.
There are three (3) key components to controlling
hepatitis B. These include treating infected persons,
interrupting the spread of the infection transmission and
reducing the mortality associated with advanced hepatic
disease and HCC [65]. A vaccine against hepatitis B has
been available since 1982. The vaccine is safe and 95 %
effective in preventing infection and the development of
chronic disease and HCC due hepatitis B [5]. For in-
stance, in Senegal, vaccinations have reduced infection
rates among children from 18.7 to 2.2 %, whereas in
Gambia, it has led to a reduction in infection rate from
10 % to less than 1 % [66]. Ghana introduced Hepatitis
B vaccination of babies as part of the Expanded
Programme of Immunization (EPI) in 2002 [13]. Babies
from 6 weeks onwards receive the pentavalent vaccine
(diphtheria, polio, tetanus, hepatitis B, influenza type B).
The coverage of EPI is good in all regions of the country
and among the highest in Sub-Saharan Africa [67]. The
introduction of the HBV vaccine in 2002 may have by
inference contributed to the lowering of prevalence rates
as studies published in the post vaccine introduction
periods 2003–2015 recorded lower HBV prevalence
rates than the pre-vaccine introduction period (1995–
2002).
On the other hand, although, Ghana’s National Health
Insurance Scheme (NHIS) introduced in 2003, aims to
improve access to health services by eliminating finan-
cial barriers (particularly out-of pocket payments), hepa-
titis B screening and vaccination in Ghana outside EPI
are still not covered under the scheme. Screenings are
only covered and prescribed at hospitals for patients sus-
pected to be reactive to hepatitis B and/or C. Hepatitis B
immunoglobulin G and hepatitis B monovalent vaccine
for babies born to hepatitis B reactive mothers are also
not covered by the NHIS [68]. These may have all ham-
pered effective control of the disease over the last couple
of years.
Epidemiological studies have demonstrated that rapid
urbanization, overpopulated cities and poor socioeco-
nomic conditions such as lack of access to clean water
and sanitation are implicated in the burden of HBV [69].
The World Bank notes that over the last 2 decades,
there has been a steady increase in the proportion of
Ghanaians with access to portable water with current
rates exceeding 88 % [70]. Nevertheless, less than 15 %
of Ghanaians have access to proper sanitation [71].
Martinson et al. [48], has demonstrated that the im-
provement of socioeconomic conditions may lead to a
decreasing exposure to viral hepatitis such as HBV in
Ghana. Hence, the apparent reported lower prevalence
rate within the period 2003–2015, may have been due to
the combined effect of vaccine introduction and im-
provement in some socioeconomic conditions. Better so-
cioeconomic improvement and vaccination coverage in
urban areas compared to rural areas may underline the
difference in HBV prevalence rates difference between
these two settings. However, it is unclear the extent to
which factors such as vaccination and socioeconomic
conditions have played in the slight regional variations
in HBV prevalence across the country.
Although, there exist significant gaps in the evidence
documenting the burden of HBV on individuals, the
healthcare system and the country as whole, the cost as-
sociated with HBV in Ghana can be enormous because
of the high morbidity and mortality associated with end-
stage liver disease, cirrhosis and HCC. Blankson et al.,
identified that over 2 in 5 cirrhotic patients in Ghana
had chronic HBV [8]. The cost of oral treatment for
HBV in Ghana is about GHC 300-400 (USD100-150) a
month or same weekly to take an injection for 48 weeks
as a way of managing the condition [72]. This cost is
enormous and one that majority of Ghanaians cannot af-
ford. Even if this was to be publicly funded, the impact
on health expenditure would be significant. Moreover, as
identified from the studies, the most prevalent
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population was 16–39 years covering some of the most
productive age groups. Thus the economic impact of
HBV in Ghana through loss of life and absenteeism from
work cannot be underestimated.
Addressing Ghana’s high HBV prevalence should re-
main a key national priority and one that needs strategic
public health interventions. In 2014, the World Health
Assembly adopted the second WHO resolution on viral
hepatitis (WHA67.6), providing guidance to govern-
ments on how to prioritize actions to tackle all forms of
viral hepatitis in a coordinated manner [73]. Subse-
quently, the recently released WHO guidelines on the
management of chronic hepatitis B highlights the im-
portance of adopting a simplified public health approach
to controlling the virus [74]. The key highlights of this
guideline includes developing publicly-funded screening
and treatment programmes and providing universal
access to hepatitis B prevention, care and treatment.
Scaling up this programme in Ghana will have two main
benefits. Firstly, it will expand access to the general
population. And secondly, it will strengthen the diagnos-
tic services and laboratory infrastructure to support care.
In line with this, Hepatitis B vaccination should be cov-
ered by the NHIS, preferably for every citizen. If this is
not achievable owing to resource limitations, it should
be made available at least to all family members/close
contacts of persons with hepatitis B in efforts to reduce
horizontal transmission of the disease.
Effectively tackling HBV burden calls for a stronger
political will and a wider social involvement. The aim
will be to solidify the inclusion of HBV prevention in the
overall national health agenda and salvage the needed
resources to execute the necessary interventions.
Lemoine et al. makes interesting reference to lessons
learnt from the HIV/AIDS epidemic and advocates that
the same energy and mobilization must be applied to
fighting viral hepatitis such as HBV [1]. Within the HIV/
AIDS domain, pressure from patient advocacy groups
and civil societies for instance “pushed” policy makers
and drug manufacturers to lower the cost of ARTs to
the current level of around USD100 per person per year
from about $10,000 per patient per year in the early
2000s [1]. This has subsequently had tremendous impact
on the number of individuals receiving ART. Also inte-
grating viral hepatitis programmes into the existing na-
tional health programmes around Tuberculosis (TB) or
HIV may allow shared synergies in terms of the pro-
gramme’s success and limit its cost [1, 65].
This study raises a number of key issues regarding
HBV research in Ghana. Firstly, while there seems to be
a positive trend of increased research in this area charac-
terized by 60 % of papers being published in the last
5 years, there are widespread regional variations in the
level of research. About 75 % of studies were conducted
in two regions (Ashanti & Greater Accra) and in four re-
gions it was not possible to derive aggregate data due to
limited number of studies. Moreover, studies were con-
centrated in adult populations giving little information
about HBV prevalence in children which is a better pre-
dictor of the level of maternofaetal transmission [48].
Likewise most studies provided no information regard-
ing the relationship between prevalence and socio-
demographic characteristics such as religion, income,
and type of occupation all of which are recognized pre-
dictors of HBV prevalence [75]. Further research in
these areas would be needed to fully understand the dy-
namics of HBV burden in Ghana.
Limitations
The accuracy of detection of active HBV infection de-
pends on a number of factors such as the screening
method employed [25]. The distinction of active from
past infection usually requires the adoption of other
methods including the identification of HBV IgM and
HBV markers. Advanced methods such as DNA testing
may be able to detect the presence of hepatitis even be-
fore the appearance of antibodies [25, 76]. Since, our re-
view was conducted over a 20-year period, the studies
involved may have used different generations of screen-
ing kits and there may be a variation in the sensitivity
and specificity which could impact on the difference in
prevalence rates between the different study publication
periods. The majority of the studies analyzed used con-
venient samples and the risk profile may not be fully
representative of the Ghanaian population. Moreover, of
the 105,435 population size involved in the 30 studies, a
significant proportion (89.1 % n = 93,990), were among
blood donors who are populations with specific charac-
teristics. In Ghana, women and children are not frequent
donators of blood as compared to young and middle-
aged men. Hence, the HBV prevalence, may be more
representative of a young and middle-aged male popula-
tion. Moreover, with the regional imbalance in the num-
ber of studies, the overall prevalence may not be entirely
representative of a true national prevalence. Regardless
of the above limitations, our review provides a useful es-
timate of the prevalence of HBV in Ghana as it is similar
to prevalence rates quoted by some experts and also
comparable to results from other countries within the
sub-region [3, 16, 17]. Also, with the majority of studies
published recently, the overall prevalence is likely to re-
flect current situation.
Conclusion
In conclusion, there is a high burden of chronic HBV in-
fection among Ghanaians. This is a preventable disease
and indeed one that can be eradicated by vaccination.
Addressing the challenges of HBV infection in Ghana will
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require multi-level approaches that includes population-
wide educational interventions and a strengthening of the
Ghanaian health system. There is urgent need for the gov-
ernment of Ghana and its international partners to
prioritize HBV control as done successfully for conditions
such as HIV, Malaria and TB. This is necessary to prevent
a potential future explosion of HBV in Ghana.
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